Judge Rejects KV Sanctions Bid In Ritalin ANDA Suit

Law360, New York (July 22, 2008, 12:00 AM EDT) -- KV Pharmaceutical Co. has lost its bid for sanctions against pharmaceutical firms Celgene Corp. and Novartis Pharma AG for failing to conduct an infringement analysis before suing KV to stop it from marketing a generic version of Ritalin LA, which treats attention deficit disorder.

Judge Susan D. Wigenton of the U.S. District Court for the District of New Jersey denied KV’s motion with prejudice on July 17, holding that a patent owner can file suit after determining a party has submitted an Abbreviated New Drug Application...
To view the full article, register now.